of VEGFR1 in the cornea leads to a VEGF-trap antiangiogenic effect. Invest Ophthalmol Vis Sci. 2015;56:5450-5456. DOI:10.1167/ iovs.14-16248 PURPOSE. To determine the possible antiangiogenic effect of metalloproteinase (MMP) 14 cleavage of vascular endothelial growth factor receptor 1 (VEGFR1) in the cornea.
T he membrane-bound matrix metalloproteinase 14 (MMP14, MT1-MMP) is one of the most well-studied members of the metalloproteinase family, both in vivo and in vitro, and in both normal physiological and disease models. Matrix metalloproteinase 14 has a variety of roles in processes that involve angiogenesis, including wound healing, inflammation, and cancer invasion and metastasis. [1] [2] [3] [4] [5] [6] In the MMP14 knockout (KO) mouse, 7 corneal angiogenesis fails to occur following normal stimulation techniques, including the application of basic fibroblast growth factor (bFGF). 7 Other experiments have shown that angiogenesis and tumor growth are impaired in the absence of MMP14. 4, [8] [9] [10] Matrix metalloproteinase 14 has been implicated in angiogenesis not only as a proangiogenic factor (e.g., MMP-dependent endothelial cell migration 8, 11 ) but also as an antiangiogenic factor (e.g., in corneal epithelium 6, 12 ), and both up-and downregulation of MMP14 have been implicated in a variety of disease models of angiogenesis. 9, 13, 14 In most of these systems, the most crucial role of MMP14 is thought to be the remodeling of the extracellular matrix (ECM), where it acts to modify essentially all components of the ECM, including collagens, proteoglycans, and fibronectins. 5, 15, 16 The role of MMP14 in the proteolysis of other transmembrane or nonmatrix extracellular proteins remains less well characterized. 17, 18 In this capacity, it is best known for its ability to cleave, in conjunction with tissue inhibitor of metalloproteinase 2 (TIMP2), its fellow matrix metalloproteinase 2 (MMP2) from its pro-form to its active form. 2, 19 Previous studies have indicated that the vascular endothelial growth factor receptor 1 (VEGFR1) is cleaved in response to stimulation by its ligand, VEGF. 20, 21 The agent performing this cleavage has not been identified, but it is suspected to be a member of the metalloproteinase family because cleavage can be blocked by GM6001, a general inhibitor of some metalloproteinases. We hypothesize that MMP14 might be the factor responsible for VEGFR1 cleavage.
Vascular endothelial cells express the VEGF receptors VEGFR1 and VEGFR2, which have overlapping and complementary roles during angiogenesis. 22 Both VEGFR1 and VEGFR2 (but not VEGFR3) bind VEGF, but with differing affinities and downstream effects. Vascular endothelial growth factor receptor 1 has a much higher affinity for VEGF (approximately 103 greater) compared to VEGFR2, but VEGFR2 initiates a much higher level of tyrosine kinase activity (approximately 103 greater than VEGFR1). [23] [24] [25] [26] Vascular endothelial growth factor receptor 1 forms both homo-and heterodimers with family receptors on endothelial cells, in varying proportions depending on conditions. 27, 28 While much is known about the individual activity of each of these important receptors, less is known about the cellular function of heterodimers with family receptors. It has been suggested that the principal role of VEGFR1 may be to act as a modulator of VEGFR2 activity because VEGFR1 initiates almost no tyrosine kinase activity itself 25 and is thought to initiate less tyrosine kinase activity than the VEGFR2. 29 Alterations to levels of VEGFR1 on the cell surface could, therefore, have a major impact on VEGFR2-induced kinase activity during the initiation and maintenance of angiogenesis. 27 In addition, soluble VEGFR1, formed by alternative splicing, can trap free VEGF and thus serve as a specific antagonist of VEGF function, 30 acting as an antiangiogenic factor.
To test our hypothesis that MMP14 cleaves VEGFR1 during angiogenesis, we conducted in vitro proteolytic experiments. Our results provide evidence confirming our hypothesis that VEGFR1 is cleaved by MMP14, and give important insights into the specificity of this activity as well as a potential functional purpose for the products of VEGFR1 cleavage.
MATERIALS AND METHODS

In Vitro Proteolysis
Recombinant mouse (rm) VEGFR1 (R&D Systems, Minneapolis, MN, USA) was incubated alone or with the catalytic domain of MMP14 (cdMMP14; Calbiochem, Billerica, MA, USA). Recombinant mouse VEGFR1 also was incubated with heat-inactivated (10 minutes at 1008C) MMP14 (MMP14*, Calbiochem) or GM6001 (Calbiochem). Matrix metalloproteinase 2 (Calbiochem) was used as a positive control for these reactions. Reactions were allowed to occur for 4 hours at 378C. Purification of 59.8-kDa cleaved VEGFR1 fragment at the Nterminus was done by pulldown with Ni-NTA agarose beads (Qiagen, Valencia, CA, USA) to remove 35-kDa C-terminal fragment containing IgG and His-tag. Unbound 59.8-kDa cleaved VEGFR1 fragment was separated from another unbound small 21-kDa (Ig domains 6-7) fragment using Amicon 30 K membrane filter (Millipore, Billerica, MA, USA).
Western Blots
The products of completed reactions were separated by 4% to 20% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under nonreducing conditions unless stated otherwise and transferred to nitrocellulose (NC) membranes. Reducing conditions, when used, consisted of treatment with 100 mM b-mercaptoethanol solution followed by boiling for 10 minutes. Sections were stained with Coomassie blue and then destained with acetic acid and methanol. Western blot experiments were blocked using 5% milk or 3% bovine serum albumin (BSA). Membranes were incubated overnight with primary antibody (anti-His tag, GenScript, Piscataway, NJ, USA; anti-p-ERK or anti-ERK, Santa Cruz Biotechnology, Santa Cruz, CA, USA; anti-VEGFR1 and anti-MMP14, Abcam, Cambridge, MA, USA; anti-actin, Cell Signaling Technology, Inc., Danvers, MA, USA). The NC membrane was incubated with fluorescence 800CW-conjugated secondary antibody (Li-Cor, Lincoln, NE, USA). Protein bands were detected by Li-Cor Odyssey system.
Wild-type and MMP14 Dexon4 mouse corneal fibroblasts were isolated, cultured, and prepared as described previously. 31 Twenty micrograms total lysates from cultured wild-type and MMP14 Dexon4 (exon 4 deleted) mouse corneal fibroblasts was subjected to Western blot to compare VEGFR1 levels.
Edman Degradation
Matrix metalloproteinase 14-cleaved rmVEGFR1 was subjected to SDS gel electrophoresis, transferred to a polyvinylidene difluoride (PVDF) membrane, and stained with Coomassie blue. Bands were excised and sequenced by capillary Edman degradation. The sequences derived from the Edman degradation were compared with mouse VEGFR1 protein sequences.
SPR Analyses
Surface plasmon resonance (SPR) analyses were performed using a BIAcore T200 instrument (GE Healthcare, Marlboro, MA, USA). Recombinant mouse VEGFR1 and the 59.8-kDa N-terminal VEGFR1 fragment (derived from rmMMP14 cleavage of rmVEGFR1) were immobilized on a CM5 sensor chip (Series S Sensor Chip CM5; GE Healthcare) using standard amine coupling. In short, flow channels were activated by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrocholoride (EDC)/Nhydroxy succinimide (NHS) mixture, and each protein was immobilized followed by ethanolamine blocking of unoccupied surface area at 258C. Blank immobilization was performed on flow channel 1 as a control. Immobilization levels of flow channels 2 (rmVEGFR1) and 4 (59.8-kDa cleaved VEGFR1) were 3130 and 2736 response units (RU), respectively. Vascular endothelial growth factor-A 165 or Placental growth factor (PlGF) binding was measured at a flow rate of 20 lL/min in running buffer PBS-P (0.5% Surfactant P20 [Tween 20], pH 7.4) containing varied concentrations (0-20 nM at 2-fold dilution) of analyte proteins, unless otherwise indicated. Data were normalized with blank (enthanolamine) RU values. BIAcore T200 evaluation software v2.0 and SigmaPlot 12.0 (Systat Software, San Jose, CA, USA) were used to fit the data to a single rectangular hyperbolic curve to determine equilibrium dissoci-
, was used to plot RU and corresponding concentration, where y is the response, y max is the maximum response, and x is the concentration of analyte (VEGF-A 165 or PlGF).
VEGF-A 165 Binding Affinity for the 59.8-kDa N-Terminal VEGFR1 Fragment of MMP14-Cleaved rmVEGFR1
For the assay of VEGF-A 165 binding affinity for the 59.8-kDa Nterminal VEGFR1 fragment of MMP14-cleaved rmVEGFR1, 100 ng of rmVEGFR1 and the N-terminal 59.8-kDa fragment resulting from cleavage of rmVEGFR1 by MMP14 were coated onto separate wells of a 96-well clear-bottom plate. Wells were washed with PBS to remove unbound protein and blocked with 3% nonfat milk/PBS. Vascular endothelial growth factor-A 165 (0, 1, or 10 nM; R&D Systems) was added to wells and incubated. Anti-VEGF-A 165 (R&D Systems) conjugated to horseradish peroxidase (HRP) was added to capture the receptor/VEGF-A 165 complex. Chemiluminescence was read on an enzyme-linked immunosorbent assay (ELISA) reader (BioTek, Winooski, VT, USA).
Cell Proliferation Assays
Calf pulmonary artery endothelial cells (CPAEs) were maintained with endothelial cell growth medium including supplements (EBM-2; Lonza, Allendale, NJ, USA). First, 3 3 10 3 CPAEs were seeded in 96-well clear-bottom plates and then incubated overnight. Cells were washed with PBS and then incubated in 100 lL EBM-2 containing 0.5% fetal bovine serum for 6 hours for serum starvation. Cells were then treated for 48 hours with various concentrations (2-fold dilution of 1 to 0.015 lg/mL) of purified 59.8-kDa N-terminal VEGFR1 fragment that had been pre-exposed to 10 ng/mL VEGF-A 165 for 30 minutes. Cells treated with VEGF-A 165 alone were used as a positive control, which is considered the reference of 100% proliferation. Bromodeoxyuridine (10 M; Roche, Mannheim, Germany) was added for measurement of cell proliferation following the manufacturer's instructions.
RESULTS
MMP14 Cleaves VEGFR1, but Not VEGFR2 or VEGFR3, In Vitro
Recombinant VEGFR1 was incubated with MMP14 for 4 hours (Fig. 1A, lane 4) . Reactions were allowed to occur for 4 hours at 378C in order to maximize enzyme activity of the MMP14. Matrix metalloproteinase 14 cleaved VEGFR1 in a concentration-dependent manner (Fig. 1B) ; complete cleavage was achieved with 200 ng MMP14/1 lg VEGFR1. Under nonreducing conditions, three distinct cleavage products of approximately 70, 59.8, and 21 kDa were produced. Cleavage required only the MMP14 catalytic domain (Fig. 1A, lane 4) and did not occur when the MMP14 catalytic domain was heat inactivated prior to incubation (marked as MMP14* in Fig. 1A, lanes 2 and  5) . Cleavage was completely blocked by the general MMP inhibitor GM6001 (Fig. 1A, lanes 6 and 7) . These results indicate that MMP14 proteolysis may act to modulate VEGFR1 levels on endothelial cells during angiogenesis.
Characterization of VEGFR1 Fragments Produced by MMP14 Cleavage In Vitro
We next explored whether the fragments produced by MMP14 cleavage of VEGFR1 include domains 1 to 7 of VEGFR1. Fragments were exposed to nonreducing and reducing conditions. Analysis revealed that the 70-kDa fragment is a dimer (Fig. 1C) , while the 59.8-and 21-kDa fragments are monomers. Western blotting furthermore showed that the 70-and 35-kDa fragments were labeled by an anti-His tag antibody under the nonreducing condition and reducing condition, respectively. This reveals that it contains the C-terminal domain (35-kDa) of rmVEGFR1. This was also confirmed with gels stained by Coomassie blue.
Loss of MMP14 Results in an Accumulation of VEGFR1 in Cornea Fibroblasts
To investigate the effects of MMP14 on the VEGFR1 level in cells, we evaluated VEGFR1 levels in wild-type and MMP14 Dexon4 mouse cornea fibroblasts. 31 We used cells derived from MMP14Dexon4 mouse that contain no catalytic domain of MMP14, which disabled the cleavage function of MMP14. Western blotting results with cell lysates showed that a higher level of VEGFR1 remained in MMP14 Dexon4 cells than in wildtype cells (Fig. 1D) . These results indicate that MMP14 may be responsible for cleaving VEGFR1 in cornea fibroblast cells, and the loss of MMP14 results in an accumulation of VEGFR1.
MMP14 Binds VEGFR1 to Cleave
We observed that MMP14 cleaved VEGFR1, and we hypothesized that MMP14 may bind to VEGFR1 in order to cleave it. The SPR technique was used to determine binding affinities of MMP14 to VEGFR1 for direct comparison. Sensorgrams of a series of increasing concentrations of MMP14 flown on a VEGFR1-immobilized CM5 sensor surface are shown ( Fig. 2A) with the fitting curve (Fig. 2B) . The determined K D value for VEGFR1 was 1.26 6 0.42 (lM), indicating that MMP14 interacts only with VEGFR1. These results support our hypothesis.
Sequencing of MMP14-Cleaved VEGFR1 Fragments
Once we confirmed that MMP14 binds and cleaves VEGFR1, we further analyzed cleaved VEGFR1 fragments by Edman degradation (Fig. 2C ). This analysis revealed that MMP14 cleavage of VEGFR1 produces an N-terminal fragment (59. 
The N-Terminal Product of MMP14 Cleavage of VEGFR1 Binds VEGF-A 165
Cleavage of VEGFR1 by MMP14 produces an extracellular Nterminal fragment that contains the complete VEGF binding Total protein lysates from wild-type and MMP14 Dexon4 mouse corneal fibroblasts were subjected to Western blotting using anti-VEGFR1 antibodies. Blots reveal that no MMP14 activity is produced by MMP14 Dexon4 cells (row 2) and that VEGFR1 accumulates in MMP14 Dexon4 fibroblasts and is virtually eliminated in wild-type fibroblasts (row 1). Anti-actin was used as an internal control (row 3). *70-kDa fragment; **59.8-kDa fragment; ***21-kDa fragment. 
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IOVS j August 2015 j Vol. 56 j No. 9 j 5453 domain. We therefore used an ELISA to determine the binding affinity between VEGF-A 165 and the N-terminal cleavage fragment. Our investigation of the binding capacity of VEGF-A 165 to VEGFR1 and the 59.8-kDa N-terminal VEGFR1 fragment revealed that the N-terminal fragment bound to VEGF-A 165 but at a lower affinity than intact VEGFR1 (Fig. 3A) . Surface plasmon resonance was used for further quantification of the binding affinities of VEGFR1 and the 59.8-kDa N-terminal VEGFR1 fragment with VEGF-A 165 . The determined binding affinity (K D ) value between VEGF-A 165 and VEGFR1 (Fig. 3B) was 0.62 6 0.37 nM. The K D for the 59.8-kDa N-terminal VEGFR1 fragment (Fig. 3C ) was 1.16 6 0.32 nM. The SPR results suggest that the binding affinity of VEGFR1 is 1.87 stronger than that of the 59.8-kDa fragment. Additionally, we further investigated whether other known ligands of VEGFR1 such as PlGF could recognize and bind to 59.8-kDa cleaved fragments using SPR. We found that PlGF indeed showed binding to both VEGFR1 and 59.8-kDa cleaved VEGFR1 fragments with binding affinities of 6.3 nM and 13.0 nM, respectively (Fig. 3D) . The K D value of the 59.8-kDa fragment was two times weaker than that of the VEGFR1, which is similar to that of VEGF-A 165 .
N-Terminal VEGFR1 Cleavage Product Inhibits VEGF-A 165 -Induced Cell Proliferation
Last, we sought to determine whether the 59.8-kDa Nterminal fragment produced by MMP14 cleavage of VEGFR1, which we have shown effectively binds VEGF-A 165 , might function to inhibit VEGF-A 165 -induced cell proliferation by binding free VEGF-A 165 , thus preventing it from binding to VEGFR1 or VEGFR2 on the cell surface. CPAEs were stimulated for 10 minutes with either VEGF-A 165 alone (10 ng/mL) or VEGF-A 165 that had been preincubated with 1 lg/ mL of the 59.8-kDa N-terminal VEGFR1 fragment. We observed that activation of p-ERK protein by VEGF-A 165 alone (Fig. 4A, lane 2) was reduced in CPAEs by preincubation of VEGF with the N-terminal fragment (Fig. 4A, lane 3) . In addition, CPAEs were incubated with either VEGF-A 165 alone (10 ng/mL) or VEGF-A 165 that had been preincubated with increasing concentrations of the 59.8-kDa N-terminal VEGFR1 fragment (0-1 lg/mL at 2-fold dilution). After a 48-hour incubation period, we observed that VEGF-A 165 -induced cell proliferation was reduced and eventually eliminated in a dosedependent manner (Fig. 4B ).
DISCUSSION
Matrix metalloproteinase 14 is upregulated in many tissues during angiogenesis. 13 It is, in particular, upregulated in tip cells that lead angiogenic vessel growth. 32 The most well known function for MMP14 at the angiogenic front is ECM remodeling and, specifically, the activation of the gelatinase MMP2. 19 Matrix metalloproteinase 14 has been shown, however, to be involved in the canonical VEGF-and bFGFstimulated angiogenic pathways, 33, 34 although the specific role of MMP14 in these processes remains unclear. Matrix metalloproteinase 14 is generally regarded as proangiogenic because it is upregulated during angiogenesis in endothelial tissue and loss of MMP14 results in a loss of the ability of endothelial cells to form new vessels in response to bFGF. 7, 13, 33 In the present study, we aimed to determine whether MMP14 interacts with the VEGF-VEGFR signaling axis by directly cleaving the membrane receptors in the VEGF family. We found that MMP14 cleaves VEGFR1 in vitro (Figs. 1A, 1B) , that this cleavage produces three distinct fragments (70, 59.8, and 21 kDa), and that it requires the catalytic domain of MMP14 (Fig.  1B) . 35 We followed these results with experiments aimed at exploring possible antiangiogenic functions for the specificity of MMP14 cleavage of VEGFR1, as well as mechanisms through which the cleavage products might act.
Vascular endothelial growth factor receptor 2 has been previously attributed with the direct activation, via tyrosine kinase activity, of multiple signaling cascades that are required for angiogenesis. It has been proposed that a primary function of VEGFR1 might be to prevent the initiation of these signaling cascades through the maintenance of less functional VEGFR2. We found that loss of MMP14 catalytic function in endothelial cells results in an increase of VEGFR1 in the cell membrane (Fig. 1D) . We therefore hypothesized that MMP14 cleavage of VEGFR1 may act to increase N-terminal VEGFR1 fragment levels in the extracellular milieu resulting in trapping free VEGF-A 165 to decrease the activation of VEGFR2 signaling on the cell surface and thereby enhance the antiangiogenic potential of the endothelial cell.
We found that cleavage of VEGFR1 by MMP14 occurs at two locations, both within the extracellular domain. The 59.8-kDa N-terminal VEGFR1 fragment is of particular interest because it contains Ig domains 1 through 5, which includes the ligand binding domains (Ig domains 2-3) for VEGF ( Fig. 2C ; Table) . We determined that this N-terminal fragment is capable of binding VEGF-A 165 but less than intact VEGFR1 (Fig. 3A) . Because this fragment can bind to VEGF-A 165 , we hypothesized that it may, upon shedding into the extracellular space, act in an antiangiogenic manner by acting as a trap for free VEGF-A 165 , thereby reducing the level of free VEGF-A 165 available to interact with VEGFR 2 and thus decreasing VEGF-driven angiogenesis. Indeed, our results show that the 59.8-kDa Nterminal VEGFR1 fragment reduces and eventually eliminates VEGF-A 165 -induced proliferation and p-ERK activation in endothelial cells (Fig. 4) . This is consistent with previous studies, which have shown that a naturally occurring soluble VEGFR1 (sVEGFR1), generated by alternative splicing that results in a truncated receptor very similar to the N-terminal fragment produced by MMP14 cleavage of VEGFR1, can bind free VEGF-A 165 to inhibit VEGF-A 165 -induced proliferation in human umbilical vein endothelial cells 36 and trap free VEGF-A 165 for preserving avascularity in the cornea. 30 Matrix 
